Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III omalizumab study in chronic spontaneous urticaria refractory to H1 antihistamines
2016-002273-35Phase 3
- Sponsor
- Novartis
- Start
- Jun 2016
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of omalizumab in chronic idiopathic urticaria (CIU) (3 arms), sponsored by Novartis. Primary endpoint: Change from baseline to Week 12 in weekly itch severity score.
02
Drugs
omalizumab
03
Conditions
chronic idiopathic urticaria (CIU)
Beyond the preview
Go deeper on 2016-002273-35.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-002273-35.